Related Experiment Video
Updated: Aug 3, 2026
07:27
A Simple Protocol for Platelet-mediated Clumping of Plasmodium falciparum-infected Erythrocytes in a Resource Poor Setting
Published on: May 16, 2013
Is a clinical consensus possible for the polycythaemic patients?
1Service de Médecine Nucléaire, Hôpital Saint-Louis, Paris, France.
Nouvelle Revue Francaise D'Hematologie
|April 1, 1994
Summary
This study addresses the need for consensus in managing polycythemias, a blood disorder. It re-evaluates diagnostic criteria and treatment strategies for better patient care and resource allocation.
Area of Science:
- Hematology
- Oncology
Background:
- No prior consensus conference on hematologic disorders in France.
- Polycythemias are relatively common (1-2/100,000/year) but require updated management guidelines.
- Existing diagnostic criteria from 1975 (Polycythemia Vera Study Group) need revision due to new diagnostic tools.
Purpose of the Study:
- Establish a consensus on the initial evaluation, treatment, and survey of polycythemias.
- Redefine diagnostic criteria for polycythemia vera.
- Optimize the use of diagnostic tests and preventive treatments for vascular complications.
Main Methods:
- Review of existing literature and diagnostic criteria.
- Discussion of new diagnostic methods like erythropoietin and stem cell cultures.
- Analysis of treatment options, including 32P, hydroxyurea, and verteporfin, considering risks and benefits.
Main Results:
- Identified obsolete diagnostic examinations and introduced new ones.
- Highlighted the need for cost-effective biological tests.
- Emphasized the importance of predicting and preventing vascular complications.
- Raised questions regarding optimal treatment strategies and patient monitoring.
Conclusions:
- A consensus is needed to update the definition and management of polycythemias.
- Further research is required to clarify treatment efficacy and long-term outcomes.
- Clear guidelines are necessary for the roles of specialists and general practitioners in patient care.
More Related Videos
Related Concept Videos
01:27Disorders of Erythrocytes
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...